tiprankstipranks
Advertisement
Advertisement
4D Molecular assumed with an Overweight at Barclays
PremiumThe Fly4D Molecular assumed with an Overweight at Barclays
3M ago
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
Premium
Company Announcements
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
3M ago
4D Molecular announces employment inducement grants
Premium
The Fly
4D Molecular announces employment inducement grants
3M ago
4D Molecular Therapeutics Appoints New Chief Financial Officer
PremiumCompany Announcements4D Molecular Therapeutics Appoints New Chief Financial Officer
5M ago
4D Molecular names Kristian Humer as CFO
Premium
The Fly
4D Molecular names Kristian Humer as CFO
5M ago
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
Premium
Ratings
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position
5M ago
4D Molecular reports Q3 EPS ($1.01), consensus (98c)
PremiumThe Fly4D Molecular reports Q3 EPS ($1.01), consensus (98c)
5M ago
4D Molecular Therapeutics Closes $93.3 Million Stock Offering
Premium
Company Announcements
4D Molecular Therapeutics Closes $93.3 Million Stock Offering
5M ago
Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating
Premium
Ratings
Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Long-term Efficacy, Safety, and Financial Strength Justify Buy Rating
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100